Recent results from prevention trials using teplizumab and oral insulin initiated in stage 1 and 2 type 1 diabetes suggest that autoantibody-positive individuals with accelerated, active disease and paradoxically worse beta cell function may be primed to respond better to a disease-modifying intervention [26, 27]. This evidence concerns the gene INS and type 1 diabetes mellitus.